Comparative serological study finds anti-carbamylated protein antibodies across various connective tissue diseases, indicating limited utility for distinguishing them from rheumatoid arthritis.
OBJECTIVE: Anti-carbamylated protein (anti-CarP) antibodies are possible diagnostic biomarkers of anticitrullinated protein antibody (ACPA)-negative rheumatoid arthritis (RA). We aimed to elucidate the prevalence of anti-CarP antibodies in non-RA connective tissue diseases (CTD) because CTD are important in the differential diagnosis of ACPA-negative RA. METHODS: The sera from 266 patients with RA and 616 patients with CTD and 80 healthy controls were examined using an in-house anti-CarP ELISA. RESULTS: The prevalence and the level of anti-CarP antibodies in several CTD were comparable to those in ACPA-negative RA. CONCLUSION: Anti-CarP antibodies are not useful for differentiating ACPA-negative RA from CTD.
No takes yet. Share an insight, caveat, or question.
Nakabo et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: